Andrew C. Jackson - 03 Jun 2022 Form 4 Insider Report for Brooklyn ImmunoTherapeutics, Inc. (ERNA)

Reporting relationship: Chief Financial Officer
Issuer ticker: ERNA
Reported as of: 03 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jun 2022, 17:01:15 UTC
Prior SEC filing: 01 Jun 2022
Next SEC filing: 02 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/ Andrew C. Jackson

Key filing fact

Andrew C. Jackson filed Form 4 for Brooklyn ImmunoTherapeutics, Inc. (ERNA) on 06 Jun 2022.

Key facts

This page summarizes Andrew C. Jackson's Form 4 filing for Brooklyn ImmunoTherapeutics, Inc. (ERNA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jun 2022, 17:01.

Change

Previous filing in this sequence was filed on 01 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ERNA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +664,800
Change %
Price: $0.000000
Shares after: 664,800
Date: 03 Jun 2022
Ownership: Direct
Underlying class: Common Stock, par value $0.005 per share
Underlying amount: 664,800
Exercise price: $0.6086
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests and becomes exercisable over four years (subject to continued service), with 25% of the shares vesting on May 31, 2023 and the remaining shares vesting in 36 substantially equal monthly installments thereafter.